Abstract
Background Esophageal cancer is a serious threat to human health and causes a heavy economic burden. upper gastrointestinal imaging(UGI imaging), enhanced CT, Fecal occult blood Tumor markers such as test(FOBT) and CEA, CA125 and CA19-9 are widely used in the screening or preliminary diagnosis of esophageal cancer. However, false-positive results of UGI imaging, enhanced CT, FOBT, CEA, CA125, and CA19-9 can lead to misdiagnosis and erroneous esophagoscopy, while their false-negative results can lead to missed diagnosis and delayed treatment. It is urgent to find a convenient, economical and non-invasive diagnostic method to reduce the false positive rate and false negative rate of UGI imaging. The objective of this study was to evaluate the diagnostic value of YiDiXie™-SS, YiDiXie™ -HS and YiDiXie™-D in esophageal cancer.
Patients and methods This study included 164 subjects (malignant group, n=105; Benign group, n=59 cases). The remaining serum samples of the subjects were collected and the sensitivity and specificity of the YiDiXie™-SS, YiDiXie™ -HS and YiDiXie™-D were evaluated using the YiDiXie™all-cancer detection kit.
Results The sensitivity of YiDiXie™-SS was 99.0% (95% CI: 94.8% - 100%) and its specificity was 61.0% (95% CI: 48.3% - 72.4%). This means that YiDiXie™-SS has an extremely high sensitivity and relatively high specificity in esophageal tumors.YiDiXie ™-HS has a sensitivity of 92.3% (95% CI: 85.7% - 96.1%) and a specificity of 86.4% (95% CI: 75.5% - 93.0%). This means that YiDiXie™-HS has high sensitivity and specificity in esophageal tumors.YiDiXie™-D has a sensitivity of 83.8% (95% CI: 75.6% - 89.6%) and a specificity of 93.2% (95% CI: 83.8% - 97.3%). This means that YiDiXie™-D has relatively high sensitivity and very high specificity in esophageal tumors. YiDiXie™-SS significantly reduced the false-positive rate of UGI imaging, CT, FOBT, CEA, CA125, CA19-9 with essentially no increase in malignancy leakage.YiDiXie™-HS significantly reduced the false-negative rate of UGI imaging, CT, FOBT, CEA, CA125, CA19-9. YiDiXie™-D significantly reduces the false positive rate of UGI imaging, CT, FOBT, CEA, CA125, CA19-9. YiDiXie™-D significantly reduces the false negative rate of UGI imaging, CT, FOBT, CEA, CA125, CA19-9, while maintaining a high level of specificity.
Conclusion YiDiXie™-SS has very high sensitivity and relatively high specificity in esophageal tumors.YiDiXie™-HS has high sensitivity and high specificity in esophageal tumors.YiDiXie ™ -D has relatively high sensitivity and very high specificity in esophageal tumors. YiDiXie™-SS significantly reduced the false-positive rates of UGI imaging, CT, FOBT, CEA, CA125, and CA19-9 with essentially no increase in delayed treatment for esophageal cancer. YiDiXie ™ -HS substantially reduced the false-negative rates of UGI imaging, CT, FOBT, CEA, CA125, and CA19-9. YiDiXie ™ -D significantly reduces the false-positive rate of UGI imaging, CT, FOBT, CEA, CA125, CA19-9, or significantly reduces their false-negative rates while maintaining high specificity. YiDiXie™ tests have an important diagnostic value in esophageal cancer, and are expected to solve the problems of “high false-positive rate” and “high false-negative rate” of UGI imaging, CT, FOBT, CEA, CA125, CA19-9.
Clinical trial number ChiCTR2200066840.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
ChiCTR2200066840
Funding Statement
This work was supported by Shenzhen High-level Hospital Construction Fund, Clinical Research Project of Peking University Shenzhen Hospital (LCYJ2020002, LCYJ2020015, LCYJ2020020, LCYJ2017001).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of Peking University Shenzhen Hospital gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
The results were updated. Most tabels and results were reviesed.
Data Availability
All data produced in the present study are contained in the manuscript.
